[go: up one dir, main page]

WO2006119449A3 - Modified adenovirus containing a stabilized antibody - Google Patents

Modified adenovirus containing a stabilized antibody Download PDF

Info

Publication number
WO2006119449A3
WO2006119449A3 PCT/US2006/017196 US2006017196W WO2006119449A3 WO 2006119449 A3 WO2006119449 A3 WO 2006119449A3 US 2006017196 W US2006017196 W US 2006017196W WO 2006119449 A3 WO2006119449 A3 WO 2006119449A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenovirus containing
modified adenovirus
stabilized antibody
present
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/017196
Other languages
French (fr)
Other versions
WO2006119449A2 (en
Inventor
David T. Curiel
Nikolay Korokhov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectorlogics Inc
Original Assignee
Vectorlogics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectorlogics Inc filed Critical Vectorlogics Inc
Publication of WO2006119449A2 publication Critical patent/WO2006119449A2/en
Anticipated expiration legal-status Critical
Publication of WO2006119449A3 publication Critical patent/WO2006119449A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates generally to the fields of vector biology and gene therapy. The invention is based, in part, on Applicants' discovery that stabilization of the targeting molecule results in successful incorporation of antibody-related molecules into the adenovirus capsid. Accordingly, the present invention relates to the production of recombinant adenoviral vectors containing stabilized antibodies for cell-specific targeting.
PCT/US2006/017196 2005-05-04 2006-05-04 Modified adenovirus containing a stabilized antibody Ceased WO2006119449A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67768305P 2005-05-04 2005-05-04
US60/677,683 2005-05-04

Publications (2)

Publication Number Publication Date
WO2006119449A2 WO2006119449A2 (en) 2006-11-09
WO2006119449A3 true WO2006119449A3 (en) 2011-05-26

Family

ID=37308718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/017196 Ceased WO2006119449A2 (en) 2005-05-04 2006-05-04 Modified adenovirus containing a stabilized antibody

Country Status (1)

Country Link
WO (1) WO2006119449A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
PL1976877T5 (en) 2005-11-30 2017-09-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
CN117903302A (en) 2005-11-30 2024-04-19 Abbvie 公司 Anti-aβ globulomer antibodies, related products thereof, methods of producing said antibodies, uses of said antibodies, and methods of use
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
MX360403B (en) 2010-04-15 2018-10-31 Abbvie Inc Amyloid-beta binding proteins.
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
WO2013090806A2 (en) * 2011-12-15 2013-06-20 Washington University Porcine knob xenotype chimeric adenoviral vector for dendritic cell infection
JP6576326B2 (en) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ Oncolytic adenovirus composition
EP3132038A4 (en) * 2014-04-18 2017-11-29 Washington University Adenoviral targeting, compositions and methods therefor
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
ES2933174T3 (en) 2016-02-23 2023-02-02 Salk Inst For Biological Studi Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
JP2019536468A (en) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ Synthetic adenovirus targeting tumors and uses thereof
KR20200140848A (en) 2018-04-09 2020-12-16 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 Oncolytic adenovirus composition with improved replication properties

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555368B1 (en) * 1999-09-24 2003-04-29 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
US6841540B1 (en) * 1998-09-29 2005-01-11 The Uab Research Foundation Immunomodulation by genetic modification of dendritic cells and B cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841540B1 (en) * 1998-09-29 2005-01-11 The Uab Research Foundation Immunomodulation by genetic modification of dendritic cells and B cells
US6555368B1 (en) * 1999-09-24 2003-04-29 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use

Also Published As

Publication number Publication date
WO2006119449A2 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
WO2006119449A3 (en) Modified adenovirus containing a stabilized antibody
Michelfelder et al. Adeno-associated viral vectors and their redirection to cell-type specific receptors
WO2006042158A3 (en) Methods and compositions for improving recombinant protein production
JP2021184745A (en) Novel minimal utr sequences
WO2008010864A3 (en) Modified adenovirus hexon protein and uses thereof
EP3586868A3 (en) Liver-specific nucleic acid regulatory elements and methods and use thereof
WO2008122811A3 (en) Adenoviral vectors encoding a pathogen or tumour antigen
Pergu et al. The chaperone ERp29 is required for tunneling nanotube formation by stabilizing MSec
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
WO2001070276A3 (en) Aav5 vector for transducing brain cells and lung cells
WO2004111248A3 (en) Improved aav vector for gene therapy
WO2006015389A3 (en) Methods and compositions for enhancing the efficacy and specificity of rna silencing
WO2010138263A3 (en) Novel aav 's and uses thereof
WO2007073489A3 (en) Molecules for gene delivery and gene therapy, and methods of use thereof
WO2003094862A3 (en) tRNA SYNTHASE: MODULATORS OF ANGIOGENESIS
UA97516C2 (en) Fully human anti-vap-1 monoclonal antibody
Larsen et al. Proteome-wide identification of in vivo ADP-ribose acceptor sites by liquid chromatography–tandem mass spectrometry
MY209964A (en) Isolated modified vp1 capsid protein of aav5
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
WO2008017073A3 (en) Vector systems
EP1539937A4 (en) METHODS OF PROPAGATION OF ADENOVIRUS AND VIRUS SO OBTAINED
WO2006033999A3 (en) Modified adenovirus containing a fiber replacement protein
WO2007149246A3 (en) Cre-lox based gene knockdown constructs and methods of use thereof
Morys et al. From artificial amino acids to sequence-defined targeted oligoaminoamides
WO2010006136A3 (en) Adenovirus targeting

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06752241

Country of ref document: EP

Kind code of ref document: A2